Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.81 |
| ▸ | STAT6 | P42226 | 2/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.33 |
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | MMP2 | P08253 | 8/20 | 0.32 |
| ▸ | MMP3 | P08254 | 7/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taltobulin SCHEMBL4378011 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL13751409 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL13848320 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL58672 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL6799555 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL57119 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL6670481 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL13751415 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL16176425 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 | |
| Taltobulin SCHEMBL58356 | 1.00 | TUBB1 (0.81) | TUBB1STAT6ADAM17MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 753 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590150-B2 | Antibody against Nectin-4 and application thereof | MABWELL (SHANGHAI) BIOSCIENCE CO. LTD. (CN) | 2026-03-31 | — | — | US | claimed |
| WO-2025233682-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS AND USES THEREOF | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | claimed |
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20250313647-A1 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-09 | — | — | US | claimed |
| US-20250269047-A1 | ANTI-HUMAN B7-H3 ANTIBODY AND APPLICATION THEREOF | MABWELL SHANGHAI BIOSCIENCE CO LTD (CN) | 2025-08-28 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4580677-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| EP-4514858-A2 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4514857-A2 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4505179-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| EP-4141029-A1 | ANTIBODY AGAINST NECTIN-4 AND APPLICATION THEREOF | Mabwell (Shanghai) Bioscience Co., Ltd. (CN) | 2023-03-01 | — | — | EP | claimed |
| CN-110088086-B | Disubstituted maleimide-based linker for antibody-drug coupling, preparation method and application thereof | 迈威(上海)生物科技股份有限公司 | 2022-12-16 | — | — | CN | claimed |
| CN-115427452-A | anti-Nectin-4 antibody and application thereof | 迈威(上海)生物科技股份有限公司 | 2022-12-02 | — | — | CN | claimed |
| WO-2022170126-A2 | COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF | ADAGIO THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2022117040-A1 | ANTI-HUMAN B7-H3 ANTIBODY AND APPLICATION THEREOF | 迈威(上海)生物科技股份有限公司 | 2022-06-09 | — | — | WO | claimed |
| CN-114573695-A | Anti-human B7-H3 antibody and application thereof | 迈威(上海)生物科技股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| EP-3546448-B1 | DI-SUBSTITUTED MALEIC AMIDE LINKER FOR ANTIBODY-DRUG CONJUGATING AND PREPARATION METHOD AND USE THEREOF | MABWELL SHANGHAI BIOSCIENCE CO LTD (CN) | 2022-04-06 | — | — | EP | claimed |
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2019-11-05 | — | — | US | claimed |
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | claimed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590150-B2 | Antibody against Nectin-4 and application thereof | NECTIN4, IGSF11, IGLV6-57 | TUBB1 849/4885STAT6 1245/4885ADAM17 1795/4885 |
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | ABCB4, ABCB1, LCAT | TUBB1 659/4885STAT6 3888/4885ADAM17 908/4885 |
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | TUBB1 199/4885STAT6 2002/4885ADAM17 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.